Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

SHA - Xbrane Biopharma AB (“Xbrane” or the “Company”) has according to previously announced information resolved to carry out a directed issue of in total 1,017,488,260 shares.

Company: Xbrane Biopharma Date: 2025-07-31 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.pdf) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

![](_page_0_Picture_1.jpeg)

## Xbrane Biopharma AB ("Xbrane" or the "Company") has according to previously announced information resolved to carry out a directed issue of in total 1,017,488,260 shares.

The share issues has resulted in a change of the registered share capital and shares and votes in Xbrane. As of 31 July 2025, the total number of shares and votes in the Company amounts to 2,549,678,555. The Company's registered share capital amounts to approximately SEK 571,602,393.

## **Contacts**

Martin Åmark, CEO E: [martin.amark@xbrane.com](mailto:martin.amark@xbrane.com)

Jane Benyamin, CFO/IR E: [jane.benyamin@xbrane.com](mailto:anette.lindqvist@xbrane.com)

## **About Us**

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 23 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during 2023. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit [www.xbrane.com](http://www.xbrane.com) 

*This information is information that Xbrane Biopharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025-07-31 21:00 CEST.*

## **Attachments**

[Xbrane Biopharma AB \("Xbrane" or the "Company"\) has according to previously announced](https://storage.mfn.se/c10a0e74-6ea8-4fb9-8628-887e6121bf37/xbrane-biopharma-ab-xbrane-or-the-company-has-according-to-previously-announced-information-resolved-to-carry-out-a-directed-issue-of-in-total-1-017-488-260-shares.pdf)  [information resolved to carry out a directed issue of in total 1,017,488,260 shares.](https://storage.mfn.se/c10a0e74-6ea8-4fb9-8628-887e6121bf37/xbrane-biopharma-ab-xbrane-or-the-company-has-according-to-previously-announced-information-resolved-to-carry-out-a-directed-issue-of-in-total-1-017-488-260-shares.pdf)

Unlock Europe's Largest Financial Database—Free

Get instant access to over 2.8M filings from 8,970 companies across 44 markets. No cost. No hassle. Just results.

Save hours with instant data access
Trusted by leading financial institutions
Free forever—no strings attached

Or sign up with

Google Microsoft

Or log in with

Google Microsoft

This premium feature is designed for professionals. Upgrade your plan to gain immediate access and enhance your research capabilities.

Upgrade Now